Blog

United CEO suffers heart attack, shares drop even lower

United Continental Holdings Inc’s new chief executive has suffered a heart attack, a person familiar with the matter said on Friday, barely a month after he took on the job of improving the airline’s profitability and reputation. The board at United – the No. 2 U.S. carrier by capacity – was informed “promptly” after Oscar Munoz was taken to hospital, the person said. “We’re still gathering information about his medical

United CEO suffers heart attack, shares drop even lower

United Continental Holdings Inc’s new chief executive has suffered a heart attack, a person familiar with the matter said on Friday, barely a month after he took on the job of improving the airline’s profitability and reputation. The board at United – the No. 2 U.S. carrier by capacity – was informed “promptly” after Oscar Munoz was taken to hospital, the person said. “We’re still gathering information about his medical

Chinese firms want to build, finance California high-speed train

A team of Chinese firms, along with the Export-Import Bank of China, wants to build and finance a large part of California’s proposed 800-mile high-speed rail project. The firms expressed their interest last month in a 23-page document sent to the California High-Speed Rail Authority. The authority asked private companies from around the globe to help shape the state’s strategy to launch the first stage of its train line, considered

Chinese firms want to build, finance California high-speed train

A team of Chinese firms, along with the Export-Import Bank of China, wants to build and finance a large part of California’s proposed 800-mile high-speed rail project. The firms expressed their interest last month in a 23-page document sent to the California High-Speed Rail Authority. The authority asked private companies from around the globe to help shape the state’s strategy to launch the first stage of its train line, considered

FDA eye drug rebuff adds to Shire's woes in Baxalta pursuit

(Reuters) – Shire Plc suffered a setback for its most important pipeline medicine late on Friday, adding to the group’s problems as it pursues Baxalta Inc to forge the leading global specialist in rare diseases. The Irish company said the U.S. Food and Drug Administration (FDA) had declined to approve its new eye drug lifitegrast and had requested an additional clinical study. The news comes just over a week before